01624nas a2200397   4500000000100000008004100001260001300042653001500055653001000070653001600080653001200096653003000108653001100138653001100149653001200160653002400172653002500196653000900221653001600230653002500246653001300271653001100284653000900295100001700304700001100321700001500332700001600347700001600363245006000379856005900439300001200498490000700510050002000517520067500537022001401212       1989                            d  c1989 Sep10aAdolescent10aAdult10aClofazimine10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aleprosy10aLeprosy, Borderline10aLeprosy, lepromatous10aMale10aMiddle Aged10aMycobacterium leprae10aRifampin10aSepsis10aSkin1 aChatterjee G1 aKaur S1 aSharma V K1 aVaishnavi C1 aGanguly N K00aBacillaemia in leprosy and effect of multidrug therapy.  uhttp://leprev.ilsl.br/pdfs/1989/v60n3/pdf/v60n3a04.pdf  a197-2010 v60  aCHATTERJEE 19893 a<p>Twenty-five patients of bacilliferous leprosy (17 LL, 8 BL) were studied by the modified haemolysis method for occurrence of bacillaemia and its clearance after two multidrug therapy regimens. Acid-fast bacilli were found in 76% of all patients and in 88.2% LL and 50% BL patients. Bacillaemia occurred with significantly reduced frequency in patients with type II reaction. Acid-fast bacilli were demonstrable in peripheral blood after 1 month in one patient on MDT of an Indian Working Group and 3 lepromatous patients on WHO multidrug therapy. However, bacillaemia could not be demonstrated in any patients after 2 and 3 months of treatment with both regimens.</p>  a0305-7518